West Virginia Changes Prior Authorization Law After Man's Treatment Delay and Death

Why It Matters

The reform reduces dangerous treatment delays in oncology and sets a precedent that could reshape prior‑authorization practices nationwide, improving patient access and lowering administrative burdens for providers and insurers.

Key Takeaways

• HB 4965 allows alternative approved treatments without new prior authorization
• Prior authorization cited as biggest patient‑care barrier in KFF poll
• Eric Tennant’s denied $50k histotripsy illustrates fatal appeal delays
• 96.6% of oncologists say insurers block recommended treatments
• COA urges overhaul of prior authorization for guideline‑concordant care

Pulse Analysis

Prior authorization has become a choke point in U.S. health care, especially for time‑sensitive oncology therapies. A February KFF poll placed it ahead of finding a clinician, scheduling, or paying for care, underscoring patient frustration. West Virginia’s new HB 4965, signed by Governor Patrick Morrissey, directly addresses this friction by allowing members of the Public Employees Insurance Agency—about 215,000 workers—to switch to an equally effective, lower‑cost treatment without filing a fresh authorization. The law was catalyzed by the tragic case of Eric Tennant, whose $50,000 histotripsy request was delayed until his disease progressed beyond eligibility.

The legislation arrives as part of a broader bipartisan push to curb utilization management excesses. In June 2025, HHS Secretary Robert Kennedy Jr. and CMS Administrator Mehmet Oz secured industry commitments to streamline prior‑authorization workflows, and more than 30 states have already enacted reforms, according to ASCO. The Community Oncology Alliance’s February 2026 survey revealed that 96.6% of independent oncology practices see insurer policies obstructing physician‑recommended care, while nearly 90% have added staff solely to manage paperwork. COA now calls for a complete overhaul of the prior‑authorization system for guideline‑concordant cancer care.

For insurers, the West Virginia model presents both a compliance challenge and an opportunity to reduce administrative overhead. Eliminating duplicate authorizations can shorten claim cycles, lower operational costs, and improve patient satisfaction metrics—factors increasingly tied to value‑based contracts. Providers stand to benefit from faster treatment initiation, which is critical in oncology where days can affect survival outcomes. As other states watch WV’s implementation, the law could become a template for national policy, accelerating a shift toward patient‑centric authorization processes across the United States.